Drug Interaction Report
1 potential interaction and/or warning found for the following 2 drugs:
- glycerol phenylbutyrate
- probenecid
Interactions between your drugs
probenecid glycerol phenylbutyrate
Applies to: probenecid, glycerol phenylbutyrate
MONITOR CLOSELY: Probenecid may inhibit the renal excretion of metabolites of phenylbutyrate, including phenylacetate (PAA) and phenylacetylglutamine (PAGN). PAA is associated with neurotoxic effects such as somnolence, fatigue, lightheadedness, headache, dysgeusia, hypoacusis, disorientation, memory impairment, tremor, peripheral neuropathy, and seizures.
MANAGEMENT: Since plasma PAA and urinary PAGN levels may be used to help guide dosing of phenylbutyrate therapy, caution is advised if probenecid is coadministered. The potential for increased risk of PAA-induced neurotoxicity should also be considered. The prescribing information for sodium phenylbutyrate combined with taurursodiol (ursodoxicoltaurine) recommends avoiding concomitant use of probenecid.
References (4)
- (2001) "Product Information. Buphenyl (sodium phenylbutyrate)." Horizon Therapeutics USA Inc
- (2013) "Product Information. Ravicti (glycerol phenylbutyrate)." Hyperion Therapeutics Inc
- (2022) "Product Information. Relyvrio (sodium phenylbutyrate-taurursodiol)." Amylyx Pharmaceuticals, 1
- (2022) "Product Information. Albrioza (sodium phenylbutyrate-ursodoxicoltaurine)." Innomar Strategies Inc.
Drug and food interactions
No alcohol/food interactions were found with the drugs in your list. However, this does not necessarily mean no food interactions exist. Always consult your healthcare provider.
Therapeutic duplication warnings
No duplication warnings were found for your selected drugs.
Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.
Report options
- Switch to consumer interaction data
- Email this report to a friend, doctor, or patient
- Ask questions, find answers
Drug Interaction Classification
| Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit. | |
| Moderately clinically significant. Usually avoid combinations; use it only under special circumstances. | |
| Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan. | |
| No interaction information available. |
See also:
Ravicti
Ravicti (glycerol phenylbutyrate) is used to treat urea cycle disorders. Includes Ravicti side ...
Taltz
Taltz (ixekizumab) is used to treat plaque psoriasis, psoriatic arthritis, and ankylosing ...
Sodium phenylbutyrate
Sodium phenylbutyrate systemic is used for urea cycle disorders
Learn more
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
Check Interactions
To view an interaction report containing 4 (or more) medications, please sign in or create an account.
Save Interactions List
Sign in to your account to save this drug interaction list.